Skip to Content
Browse all medications
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Advanced
Phonetic
Search:
Drugs A-Z
Complete A - Z Drug Index
Drugs by Condition
Drugs by Class
Drug Side Effects
Drug Dosage
Pregnancy Warnings
Breastfeeding Information
International Drugs
Generic Drugs
Veterinary Drugs
Natural Products
Phonetic Search
Harvard Health Topics
Medical Encyclopedia
Pill Identifier
Interactions Checker
News / Alerts
FDA Medwatch Drug Alerts
FDA Labeling Changes
Daily MedNews for Consumers
Pharmaceutical Industry News
Clinical Trial News
New Drug Approvals
New Drug Applications (Pipeline)
Get News via RSS
Get News via Twitter
Drugs.com Blog
Health Professionals
Professional Resource Center
FDA Prescribing Information
AHFS DI Monographs
A-Z Drug Facts for the Professional
Drug Interactions Checker
Patient CareNotes for the Professional
Natural Products Database
Medical Conferences
Pharmaceutical Company Directory
Medical Dictionary
Phonetic Drug Search
Community
Ask Medical Questions
Join Support Groups
Forum - Discussion Boards
Mednotes
Apps
Home
›
News
›
Clinical Trials
› Archive
Clinical Trial News Archive
Get news
By email
or subscribe to our
News feeds
.
All News
Consumer
Pharma
New Drugs
Pipeline
Clinical Trials
April 2009
April 1
Hythiam Announces Results of Two Double-Blind, Placebo-Controlled Studies on Impact of PROMETA Treatment Program for Alcohol Dependence
Interleukin Genetics Presents Research Linking Vertebral Fractures to Gene Variations in Asian Women With Osteoporosis
Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder
April 2
Labopharm Reports Results for Phase III Study on Twice-daily Tramadol-acetaminophen Formulation
IDEA reports results from a prospective 3 years phase III study of Diractin (ketoprofen in Transfersome gel)
Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
April 3
Phase III Study of Gilead's Darusentan for Resistant Hypertension Meets Primary Endpoints
New Study Demonstrates Improvements in LDL-Cholesterol on Top of Statin Therapy with HEP-40, a Novel Natural Product
April 6
Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
Zosano Pharma, Inc. Presents Positive Phase 2 Results of Its Needle-Free Osteoporosis Therapy
April 7
Oncolytics Biotech Inc. Announces Positive Results of U.K. Phase II REOLYSIN and Radiation Combination Clinical Trial
Cerepro Phase III trial update
AngioChem to Present New ANG1005 Clinical Data at AACR
Phase I/II Trials of Anti-Androgen Drugs Show Promise for Patients with Advanced Prostate Cancer
April 8
Study Shows Single Dose of Reclast Prevents Postmenopausal Osteoporosis for at Least 2 Years
Kiadis Pharma Reports ATIR Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations
Medivation Announces Publication in Science Describing MDV3100's Novel and Potent Anti-Androgen Properties
The Journal of Cardiac Failure Publishes Results From Celladon Corporation's First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure
bioXell S.p.A (CH) - BioXell reports top-line OAB Phase IIb results
Medifocus Inc. Reports Improved Clinical Efficacy for its Phase II, Randomized Clinical Study for the Treatment of Large Breast Cancer Tumors
ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program
Parkinson's Disease Medication Triggers Destructive Behaviors
April 9
OTHERA Announces Positive Interim Phase 2 Results of OT-551 Eye Drop Treatment for Dry AMD
New Clinical Data at ACC09 Show the CYPHER Sirolimus-eluting Coronary Stent Outperformed TAXUS LIBERTE and ENDEAVOR Stents in Key Outcome Measures
Data on AVEO Pharmaceuticals' AV-951 in Liver Cancer Model and Preclinical Activity in SCH 900105 (AV-299) to be Presented at AACR 100th Annual Meeting
Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density
April 10
ImmunoGen, Inc. Announces Presentations at the American Association for Cancer Research Annual Meeting
Curis Announces Presentations at American Association for Cancer Research Annual Meeting 2009
Lancet Publication of Juvista (INN: Avotermin) Trial Results for the Improvement of Skin Scarring
Enzyme Therapy Slows Kidney Function Decline
April 13
Crofelemer, First-in-Class Anti-Diarrheal Agent, Positive Clinical Results to be Discussed at 13th Annual US-Japan CMSP in Kolkata, India
Preclinical Data on ARIAD's Oncology Pipeline to Be Presented at the AACR Annual Meeting
Phase III Data for Gilead Sciences' Darusentan Accepted as Late-Breaker Presentation at ASH 2009
Ardea Biosciences Announces Investor and Analyst Event Participants and Webcast Information
New Approach to Progesterone Supplementation in ART Revealed in Recently Published White Paper
SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting
April 14
Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
Provenge Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
Erectile Dysfunction Treatments Do Not Appear to Damage Vision Over Six Months
Acceleron Pharma Presents Preclinical Study Results for ACE-041 at the AACR 100th Annual Meeting 2009
Genstruct to Present Results of Collaboration with Top Pharmaceutical Company at American Association for Cancer Research's Annual Meeting
Study Finds Discontinuation of Rosiglitazone Left Many Diabetes Patients Without Good Glycemic Control
Evotec AG (DE) - Evotec Reports Results of Phase II Proof-of-Concept Study with EVT 302
Low Blood Sugar Events Increase Dementia Risk in Elderly Patients With Type 2 Diabetes, Kaiser Permanente Study Finds
Oncolytics Biotech Inc. Announces Positive Results of U.K. Phase II Reolysin and Radiation Combination Clinical Trial
April 15
AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
Pro-Pharmaceuticals' DAVANAT Prevents Mucositis, a Serious Side Effect of Chemotherapy, in All 100 Cancer Patients Treated
Angiotech Pharmaceuticals, Inc. - New study shows that Zilver PTX effectively treats blockages in critical thigh artery
Telik Announces Preclinical Presentations at AACR Annual Meeting
Lorus Announces Report of Evidence of Clinical Activity in Clinical Trial of LOR-2040 Combined With Capecitabine and Oxaliplatin in the Treatment of Advanced Metastatic Solid Tumors
Medifocus Inc. Reports Improved Clinical Efficacy for its Phase II, Randomized Clinical Study for the Treatment of Early Stage Breast Cancer Tumors
American Association for Cancer Research Hosts 100th Annual Meeting
Allos Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2009
Biogen Idec Showcases Leading Multiple Sclerosis Franchise and Pipeline at the 61st Annual Meeting of the American Academy of Neurology
Sirion Therapeutics Announces Positive Results From Interim Analysis of Phase II Trial and Receives FDA Fast Track Designation for Fenretinide
April 16
MedImmune Showcases Commitment to Cancer Research at Annual Meeting of the American Association for Cancer Research
Novagali Pharma completed a new Phase II with Cyclokat in dry eye
Cytopia Presentation on VDA CYT997 at AACR Conference
Alternative Therapy for Lupus Nephritis
April 17
Pharmacyclics Updates Positive Clinical Responses in its PCI-24781 Clinical Program Targeting HDAC
Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting
Promising interim results from Hybrigenics' Inecalcitol Phase II in Combination with Taxotere(R) for Hormone-Refractory Prostate Cancer
ERYtech Pharma Presents Very Encouraging Results of Its R&D Platform at the AACR in Denver
April 20
Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
Dendreon Announces Data on Provenge Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
Lorus Therapeutics Presents New Findings for First-in-class Anticancer Drug Candidate LOR-253
Pantec Biosolutions Reports Successful Phase I Study into the Delivery of Triptorelin Using P.L.E.A.S.E.R Technology
Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology
Mersana's Second Development Candidate, XMT-1107, Shows Superior Pharmacokinetics and Anti-Tumor Activity in Studies Presented at American Association of Cancer Research Meeting
Allos Therapeutics' Pralatrexate Demonstrates Anticancer Activity in Multiple Cancer Cell Lines
Array BioPharma's ARRY-614 Demonstrates Cytokine Inhibition and Anti-Tumor Activity in Preclinical Models of Hematological Cancers
Impax Pharmaceuticals Reports Positive Achievements on its Two Leading Brand Product Candidates IPX066 and IPX056
Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference
April 21
Ardea Biosciences Announces Positive Results from a Phase 1 Study of Lead Hyperuricemia and Gout Candidate, RDEA594 and a Phase 2a Study of RDEA594's Prodrug, RDEA806
Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
AngioChem Presents New Positive Clinical Data on ANG1005 for Brain Cancers at AACR
New Pre-Clinical Data on RGB-286638 Multi-Targeted Kinase Inhibitor Presented at AACR
Array BioPharma's ARRY-543 Shows Potential Clinical Benefit in Cancer Patients
Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models
Bioalliance Pharma Presents Results on Its New Biotherapy Plasmid AMEP for Metastatic Melanoma at the American Association for Cancer Research (AACR) 100Th Annual Meeting in Denver, April 18 to 22, 2009
Seven Abstracts Featuring Exelixis Compounds to Be Presented at 2009 ASCO Annual Meeting
Isotechnika announces positive 12 month data from PROMISE trial
New study shows that re-treatment with Pegasys provides hep C patients with second chance for cure
NSLIJ Scientists to Present EKC-Cide Study Results at the GTC-Bio Conference on Ocular Diseases and Drug Discovery
Results Presented at AACR Differentiate STA-9090 in Hsp90 Inhibitor Class and Show Activity in Erlotinib (Tarceva)-resistant Lung Cancer Models
Karmanos Cancer Institute Researchers Study New Drug Combinations to Treat Childhood Leukemia
SuperGen Presents PIM kinase inhibitor SGI-1776 at American Association for Cancer Research Annual Meeting
Abstract on ˜Chemoablation of Metastatic Melanoma' Accepted for Joint Meeting of 7th World Congress on Melanoma and 5th Congress of the European Association of Dermato-Oncology
AVEO Announces Positive Finding for Triple VEGF Receptor Inhibitor AV-951 in Preclinical Model of Liver Cancer
Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
International Stem Cell Reports Excellent Preliminary Results for Skin Rejuvenation
April 22
Clavis Pharma ASA (NO) - Promising Elacytarabine Clinical Results Presented at AACR
Phase III C-08 Study of Avastin in Early-Stage Colon Cancer Did Not Meet Primary Endpoint
Vertex Pharmaceuticals to Present Data at EASL Suggesting Telaprevir's Potential for Use in a Broad Range of HCV Patients and Highlighting the Company's Expanded STAT-C Portfolio
Calistoga Pharmaceuticals Announces Presentations on CAL-101 and CAL-120 at the American Association for Cancer Research Annual Meeting
Geron Presentations on Imetelstat (GRN163L) at the AACR 2009 Annual Meeting
Curis Presents CUDC-305 Preclinical Data at the AACR 100th Annual Meeting 2009
Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
Lorus Therapeutics Announces Presentation of New Supportive Data for LOR-2040 in Acute Myeloid Leukemia
Tranzyme Pharma Announces Positive Phase 2 Results with TZP-101 for Improvement of Symptoms in Patients with Gastroparesis
Celator Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research
Anergis SA Announces Successful Results of a Phase I/IIA Clinical Trial with Subcutaneous AllerT, its Novel Product for Desensitization of Patients Allergic to Birch Pollen
GTx Announces Toremifene 80 mg Phase III ADT Clinical Trial Data to be Presented at the Annual Meeting of the American Urological Association
Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
NKTR-105 Demonstrates Superior Antitumor Activity and Improved Pharmacokinetics Over Docetaxel in Preclinical Studies Presented at AACR
Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model
AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
April 23
Pennsaid Phase 3 Study Results to be Published in Leading International PAIN Journal
Salix Presents Highly Statistically Significant Results from the Phase III Pivotal Study of Rifaximin for the Prevention and Maintenance of Remission of Hepatic Encephalopathy (HE)
April 24
Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
Vical Reports Publication of Key Research Findings for Immunotherapeutic Herpes Vaccine
ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Bristol-Myers Squibb and ZymoGenetics Present Positive 4-week Results of PEG-Interferon lambda with Ribavirin in Hepatitis C
InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)
SCYNEXIS' SCY-635 Demonstrates Clinically Relevant Single-Agent Results in a Phase 1b Study in Adults with HCV
Argos Therapeutics Presents Research Validating Feasibility and Safety of its Arcelis™ Personalized Immunotherapy Platform for HIV
Medivir: New Phase IIa Data on TMC435 in Patients with Hepatitis C Presented at the Ongoing EASL - Meeting
Opexa Publication of Tovaxin Clinical Data in Journal of Clinical Immunology
Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
Cannabis Compounds Reduce Multi-Drug Resistant Infections
New Publication of Landmark Study Demonstrates Gamunex Improves Health-Related Quality of Life in Patients with CIDP
Drug Therapy Reduces Neuroblastoma Tumor Growth in Pre-clinical Investigation
April 25
OctoPlus N.V. (NL) - OctoPlus' licensee Biolex presents Locteron Phase IIa results at EASL conference
GlobeImmune's Hepatitis C Therapeutic Vaccine, GI-5005, Improves EVR Rates to 94 percent in Phase 2 Clinical Trial
Roche Announces Collaboration to Investigate New Treatment Strategy With Tarceva in Lung Cancer
April 26
Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
Telaprevir Data Presented at EASL Show Unprecedented SVR Rates in HCV Treatment-Failure Patients in PROVE 3 Study
Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
Lancet Publishes Phase 3 Clinical Data on Basen®
April 27
Prostate Study Shows Botox May Be Safe, Effective Method for Managing Benign Prostatic Hyperplasia
Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Phase II Results for GSK1838262 (XP13512) Reported for Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
Juvaris BioTherapeutics' Vaccine Adjuvant, JVRS-100, Generates Superior T-Cell Mediated Immune Responses to Influenza in Clinical Trial
Dynavax Presents Additional Phase 3 Data for HEPLISAV Hepatitis B Vaccine at EASL Medical Conference
Sepracor Reports Preliminary Phase III Study Results for OMNARIS HFA Nasal Aerosol in Seasonal Allergic Rhinitis
Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
Curis Presents Preclinical Data for CU-903 at Keystone Symposia Event “PI3 Kinase Signaling in Disease”
Avila Presents Preclinical Data on a Novel, Orally-Available, Protease Inhibitor, AVL181, for Hepatitis C Infection at EASL 2009 Meeting
VaxInnate's Seasonal Flu Vaccine Candidate Shown Safe and Immunogenic in Phase I Study
First Ever Prospective Fracture Study in Prostate Cancer Patients on ADT Reveals These Men Are at High Risk for Skeletal Fractures
Dynavax Presents Additional Phase 3 Data for Heplisav Hepatitis B Vaccine at EASL Medical Conference
New Data Presented at AUA's Annual Conference Prove GELNIQUE (oxybutynin chloride) 10% gel is an Effective, Safe Option for Female Overactive Bladder (OAB) Patients
Theratechnologies presents additional data from studies evaluating tesamorelin at the Annual Canadian Conference on HIV/AIDS Research
Tadalafil May Effectively Treat Symptoms of BPH-LUTS in Addition to Erectile Dysfunction
CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
April 28
Ocera Therapeutics Presents Data on AST-120 in Patients With Hepatic Encephalopathy at the European Association for the Study of Liver Disease Annual Meeting
Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
Clinical Update - Debio 025 in Hepatitis C
PharmAthene Presents Data for SparVax, a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research
Presented Data Confirm That Rapaflo (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients
Data Presented at AUA Demonstrate Provenge Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
Data Show Dutasteride Reduces Prostate Cancer Diagnosis in Men With Increased Risk
Testosterone Undecanoate Achieves and Maintains Normal Testosterone Levels in Hypogonadal Men With Five Injections Per Year, New Data Show
Cempra Pharmaceuticals Inc. Announces Lead Macrolide is Active in vitro Against Clinically Significant Antibiotic-Resistant Pathogenic Organisms
April 29
Active Biotech (SE) - Active Biotech presents S100A9 as a target for quinoline compounds
Excellent Phase III results of Biofrontera's BF-200 ALA presented at dermatology congress
Isotechnika announces Phase 3 ESSENCE data meets primary endpoint in psoriasis
New data presented at American Academy of Neurology congress show 80-83% of MS patients on oral FTY720 were relapse-free for one year
MRI Data Showing Tysabri Promoted Remyelination Presented at the 61st Annual Meeting of the American Academy of Neurology
Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet
Genta Updates Late-Stage Progress of its Phase 3 Trial of Genasense in Advanced Melanoma
New England Journal of Medicine Publishes Landmark Clinical Studies of the Investigational Hepatitis C Virus Protease Inhibitor Telaprevir
Lyrica Significantly Reduced Pain and Improved Other Symptoms of Post-Traumatic Peripheral Nerve Pain, New Data Show
New Treatment Discovered for Restless Legs Syndrome Improves Sleep
Study Results Present Paradigm Shift; REDUCE Trial Shows New Hope for the Risk Reduction of Prostate Cancer
Addex Pharmaceuticals (CH) - Addex Presents Data on ADX10059 at the Annual Meeting of the American Academy of Neurology
Advaxis' Phase 1 Clinical Cervix Cancer Study Accepted for Publication in Leading Peer-Reviewed Science Journal Vaccine
New Analyses from 16-Year Follow-up Trial with Betaseron Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes
Long-Term Study with Copaxone Indicated Protective Effect on Brain Tissue in Multiple Sclerosis Patients
April 30
Phase 3 Data on VIVUS' Qnexa to Be Presented at 17th European Congress on Obesity
Novartis International AG (CH) - Novartis investigational adjuvanted (MF59) pre-pandemic avian influenza vaccine Aflunov shows long lasting, broadly cross-protective immune response
UCB (BE) - UCB announces first results from Phase III brivaracetam studies in epilepsy
Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis
LifeCycle Pharma Announces Positive Interim Results of Phase 2 Clinical Trial of LCP-Tacro for the Prevention of Organ Rejection in De Novo Kidney Transplant Patients
A Phase IIb Study Testing the Combination of Methotrexate and CF101 in Rheumatoid Arthritis Patients Failed to Achieve Primary Efficacy Endpoint
Agios Pharmaceuticals Highlights Extensive Cancer Metabolism Research at AACR
Sciele Pharma and Plethora Solutions Announce That PSD502 Demonstrates Substantial Benefit in the Treatment of Premature Ejaculation
Provectus Abstract Titled “Chemoablation of Melanoma with Intralesional Rose Bengal (PV-10)" to be Presented at ASCO Scientific Program on June 1 in Orlando
Dynavax Presents Data From Novel Universal Flu Vaccine Candidate
Solifenacin Shows Superior Tolerability Compared to Oxybutynin Immediate-Release
Study Results Published in CUTIS Demonstrate Long-Term Safety and Efficacy of Vectical (calcitriol) Ointment 3 mcg/g in the Management of Mild-to-Moderate Plaque Psoriasis
Quigley Pharma Announces Drug Study That May Reverse Diabetic Peripheral Neuropathy
First Ten-Year Follow-Up Shows That Treatment with AVONEX Leads to Long-Term Benefits in Early Multiple Sclerosis Patients
Clinical Trial Results Archive
2012
January
,
February
2011
January
,
February
,
March
,
April
,
May
,
June
,
July
,
August
,
September
,
October
,
November
,
December
2010
January
,
February
,
March
,
April
,
May
,
June
,
July
,
August
,
September
,
October
,
November
,
December
2009
January
,
February
,
March
,
April
,
May
,
June
,
July
,
August
,
September
,
October
,
November
,
December
2008
January
,
February
,
March
,
April
,
May
,
June
,
July
,
August
,
September
,
October
,
November
,
December
2007
January
,
February
,
March
,
April
,
May
,
June
,
July
,
August
,
September
,
October
,
November
,
December
2006
December
2005
April
2004
January
,
June
,
July
,
October
2003
November
More News Resources
FDA Medwatch Drug Alerts
FDA Drug Safety Labeling Changes
Daily MedNews
Pharma Industry News
New Drug Approvals
New Drug Applications
Clinical Trial Results
Generic Drug Approvals
Monthly Update Archive
Search:
Sign In
or
Register
Username
Password
Forgot password?
FDA Consumer Updates
Primatene Mist With Chlorofluorocarbons No Longer Available After Dec. 31, 2011
HCG Diet Products are Illegal
Lock it Up: Medicine Safety in Your Home
Reducing Fever in Children: Safe Use of Acetaminophen
More FDA Updates...
Recently Approved
Sklice
Sklice (ivermectin) Lotion is a pediculicide indicated for the topical treatment of head lice infestations in ...
Jentadueto
Jentadueto (linagliptin and metformin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide ...
Kalydeco
Kalydeco (ivacaftor) is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated ...
Erivedge
Erivedge (vismodegib) is a hedgehog pathway inhibitor for the treatment of patients with advanced basal cell ...
Bydureon
Bydureon (exenatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet ...
More...
Get Updates by Email
Email me:
FDA Medwatch Alerts
News Roundup
Daily
Weekly
Monthly
Email
(web4)